An Automated Assay for Precise and Sensitive Quantification of pTau217 in Plasma and Cerebrospinal Fluid

by Samantha Willis¹, Malcolm Connor¹, Joe Dunbar¹, Isabel O’Brien¹, Andreas Jeromin², and Yoav Noam¹. ¹Bio-Techne, ²ALZpath.

Accurate quantification of fluid biomarkers in blood and cerebrospinal fluid (CSF) is becoming increasingly important for the diagnosis, prognosis, and monitoring of neurodegenerative diseases. Growing evidence suggests the phosphorylated isoform of the Tau protein (pTau217) holds strong diagnostic potential as a biomarker for Alzheimer’s disease. 

Given that current methods for quantifying pTau217 in CSF and blood are time-consuming, expensive, and technically complex, we aimed to validate a fully automated immunoassay for measuring pTau217 in biofluids. 

Download This Biomarker Quantitification Poster to Discover: 

• A microfluidic approach to biomarker quantification capable of measuring up to 72 samples within 90 minutes, using 25 µl or less of sample volume 
• Analytical validation of the microfluidic Simple Plex Human Phospho Tau (T217) ALZpath assay supporting high degrees of precision, accuracy, and parallelism in both CSF and blood 
• Assessment of the utility of the assay by measuring endogenous plasma levels of pTau217 in a pilot cohort of healthy control donors and Alzheimer’s disease patients 

This poster was presented at the Society for Neuroscience (SfN)’s Neuroscience 2024 meeting in October 2024.